Kyverna Therapeutics (KYTX) Competitors $2.22 -0.09 (-3.90%) Closing price 05/1/2025 04:00 PM EasternExtended Trading$2.22 0.00 (0.00%) As of 05/1/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KYTX vs. CKPT, TECX, RGNX, OLMA, BNTC, CMPS, TKNO, ALLO, TRDA, and ARCTShould you be buying Kyverna Therapeutics stock or one of its competitors? The main competitors of Kyverna Therapeutics include Checkpoint Therapeutics (CKPT), Tectonic Therapeutic (TECX), REGENXBIO (RGNX), Olema Pharmaceuticals (OLMA), Benitec Biopharma (BNTC), COMPASS Pathways (CMPS), Alpha Teknova (TKNO), Allogene Therapeutics (ALLO), Entrada Therapeutics (TRDA), and Arcturus Therapeutics (ARCT). These companies are all part of the "pharmaceutical products" industry. Kyverna Therapeutics vs. Checkpoint Therapeutics Tectonic Therapeutic REGENXBIO Olema Pharmaceuticals Benitec Biopharma COMPASS Pathways Alpha Teknova Allogene Therapeutics Entrada Therapeutics Arcturus Therapeutics Kyverna Therapeutics (NASDAQ:KYTX) and Checkpoint Therapeutics (NASDAQ:CKPT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, community ranking, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment. Which has more volatility and risk, KYTX or CKPT? Kyverna Therapeutics has a beta of 2.57, suggesting that its share price is 157% more volatile than the S&P 500. Comparatively, Checkpoint Therapeutics has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500. Does the media refer more to KYTX or CKPT? In the previous week, Kyverna Therapeutics had 3 more articles in the media than Checkpoint Therapeutics. MarketBeat recorded 4 mentions for Kyverna Therapeutics and 1 mentions for Checkpoint Therapeutics. Checkpoint Therapeutics' average media sentiment score of 0.93 beat Kyverna Therapeutics' score of 0.81 indicating that Checkpoint Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Kyverna Therapeutics Positive Checkpoint Therapeutics Positive Does the MarketBeat Community prefer KYTX or CKPT? Checkpoint Therapeutics received 171 more outperform votes than Kyverna Therapeutics when rated by MarketBeat users. Likewise, 67.16% of users gave Checkpoint Therapeutics an outperform vote while only 64.71% of users gave Kyverna Therapeutics an outperform vote. CompanyUnderperformOutperformKyverna TherapeuticsOutperform Votes1164.71% Underperform Votes635.29% Checkpoint TherapeuticsOutperform Votes18267.16% Underperform Votes8932.84% Do insiders and institutionals hold more shares of KYTX or CKPT? 18.1% of Kyverna Therapeutics shares are held by institutional investors. Comparatively, 22.0% of Checkpoint Therapeutics shares are held by institutional investors. 2.1% of Checkpoint Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is KYTX or CKPT more profitable? Checkpoint Therapeutics' return on equity of 0.00% beat Kyverna Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kyverna TherapeuticsN/A -51.12% -37.91% Checkpoint Therapeutics N/A N/A -659.07% Which has better earnings & valuation, KYTX or CKPT? Checkpoint Therapeutics has lower revenue, but higher earnings than Kyverna Therapeutics. Checkpoint Therapeutics is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKyverna Therapeutics$7.03M13.65-$60.37M-$3.47-0.64Checkpoint Therapeutics$41K8,417.26-$51.85M-$1.43-2.88 Do analysts recommend KYTX or CKPT? Kyverna Therapeutics presently has a consensus target price of $18.33, suggesting a potential upside of 725.83%. Checkpoint Therapeutics has a consensus target price of $4.33, suggesting a potential upside of 5.18%. Given Kyverna Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Kyverna Therapeutics is more favorable than Checkpoint Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kyverna Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Checkpoint Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 SummaryKyverna Therapeutics and Checkpoint Therapeutics tied by winning 9 of the 18 factors compared between the two stocks. Get Kyverna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KYTX vs. The Competition Export to ExcelMetricKyverna TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$95.95M$2.95B$5.54B$7.93BDividend YieldN/A1.89%5.09%4.23%P/E Ratio-0.6430.0722.5718.54Price / Sales13.65494.82399.89103.29Price / CashN/A168.6838.1834.62Price / BookN/A3.176.774.25Net Income-$60.37M-$72.35M$3.22B$248.18M7 Day Performance5.71%2.14%1.07%0.91%1 Month Performance3.26%5.67%2.46%2.58%1 Year Performance-85.23%-23.57%15.74%4.02% Kyverna Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KYTXKyverna Therapeutics1.7936 of 5 stars$2.22-3.9%$18.33+725.8%-86.6%$95.95M$7.03M-0.6496News CoverageCKPTCheckpoint Therapeutics2.4003 of 5 stars$4.04flat$4.33+7.3%+194.3%$338.41M$41,000.00-2.2010Upcoming EarningsNews CoveragePositive NewsTECXTectonic Therapeutic2.5394 of 5 stars$17.92+5.3%$72.40+304.0%N/A$334.44MN/A-3.04120Upcoming EarningsShort Interest ↑Gap UpRGNXREGENXBIO4.4754 of 5 stars$6.67+12.3%$31.63+374.1%-39.3%$334.28M$83.33M-1.33370Upcoming EarningsNews CoveragePositive NewsOLMAOlema Pharmaceuticals2.4553 of 5 stars$4.75+7.5%$27.67+482.5%-49.1%$324.58MN/A-2.1770Upcoming EarningsBNTCBenitec Biopharma2.7001 of 5 stars$13.80+0.4%$24.71+79.1%+82.4%$323.62M$80,000.00-9.1420Positive NewsCMPSCOMPASS Pathways2.4237 of 5 stars$3.38+8.0%$20.20+497.6%-51.7%$313.24MN/A-1.54120Upcoming EarningsNews CoverageTKNOAlpha Teknova1.8981 of 5 stars$5.78+0.3%$8.50+47.1%+246.1%$308.87M$37.75M-7.81240Upcoming EarningsNews CoveragePositive NewsALLOAllogene Therapeutics3.4568 of 5 stars$1.42-2.1%$9.29+554.1%-42.1%$308.52M$22,000.00-0.91310Positive NewsTRDAEntrada Therapeutics2.9912 of 5 stars$7.95-2.2%$25.67+222.9%-31.7%$298.88M$210.78M5.00110Upcoming EarningsNews CoverageHigh Trading VolumeARCTArcturus Therapeutics3.1112 of 5 stars$11.00+4.5%$59.20+438.2%-55.2%$298.32M$138.39M-4.95180Upcoming EarningsNews CoveragePositive News Related Companies and Tools Related Companies CKPT Alternatives TECX Alternatives RGNX Alternatives OLMA Alternatives BNTC Alternatives CMPS Alternatives TKNO Alternatives ALLO Alternatives TRDA Alternatives ARCT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KYTX) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kyverna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kyverna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KYTX Stock Free KYTX Stock Alerts